Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up

AIDS

Volumn 16, Issue 7, 2002, Pages 1051-1058

  Hogg, Robert S ^a   Heath, Katherine ^a   Bangsberg, David ^a   Yip, Benita ^a   Press, Natasha ^a   O'Shaughnessy, Michael V ^a   Montaner, Julio S G ^a  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

Antiretroviral therapy; Effectiveness; Intermittent use of antiretrovirals; Mortality; Non nucleoside reverse transcriptase inhibitor; Nucleoside reverse transcriptase inhibitors; Population based cohort; Protease inhibitors

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CANADA; COMBINATION CHEMOTHERAPY; DRUG INTERMITTENT THERAPY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; SURVIVAL; T LYMPHOCYTE;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRITISH COLUMBIA; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; DATA COLLECTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIFE TABLES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0037013038     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200205030-00012     Document Type: Article

References (34)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. Prolongation of life and prevention of AIDS complications in a randomized controlled clinical trial of ritonavir in patients with advanced HIV disease
3. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS Trial. Italy, The Netherlands, Canada and Australia Study
4. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
5. Improved survival among HIV-infected patients after the initiation of triple-drug antiretroviral regimens
6. Sexual transmission of HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
7. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
8. Patients compliance and drug failure in protease inhibitor monotherapy
9. A preliminary study of ritonavir an inhibitor of HIV-1 protease, to treat HIV-1 infection
10. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors
11. In vivo emergency of HIV-1 variants resistant to multiple protease inhibitors
12. Transmission of HIV-1 resistant to nevirapine and zidovudine: Sydney Primary HIV Infection Study Group
13. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
14. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA
15. Acquired immune deficiency syndrome (AIDS): Interim proposal for a WHO staging system for HIV infection and disease
16. Regression models and life tables (with discussion)
17. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment
18. Virologic treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
19. Adherence: A necessity for successful HIV combination therapy
20. Adherence to triple therapy and viral load response
21. Adherence to HAART predicts progression to AIDS
22. Trends in survival of Danish AIDS patients from 1981 to 1989
23. Survival trends for patients with AIDS
24. Factors influencing survival after AIDS: Report from the multicentre AIDS cohort study (MACS)
25. The predictive value of T cell function in vitro and pre-AIDS zidovudine use for survival after AIDS diagnosis in a cohort of homosexual men in Amsterdam
26. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
27. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy
28. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS
29. Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: A predictor of long-term mortality in HIV infection
30. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple drug therapy
31. Long-term survival after initiation of antiretroviral therapy
32. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy
33. When to start highly active antiretroviral therapy in chronically HIV-infected patients: Evidence from the ICONA study